We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals
ELDN

42 hedge funds and large institutions have $2.43M invested in Eledon Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 8

5% less funds holding

Funds holding: 44 → 42 (-2)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

42% less capital invested

Capital invested by funds: $4.21M → $2.43M (-$1.78M)

Holders
42
Holders Change
-2
Holders Change %
-4.55%
% of All Funds
1.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
19
Reduced
8
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$264K
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$183K
3
Renaissance Technologies
Renaissance Technologies
New York
+$169K
4
State Street
State Street
Massachusetts
+$68.6K
5
ARTA
A.R.T. Advisors
New York
+$64.4K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$492K
2
BCM
Bridgeway Capital Management
Texas
-$417K
3
BFA
BlackRock Fund Advisors
California
-$303K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$61.7K
5
SIM
Spark Investment Management
New York
-$54K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$10K +$5.56K +29 +88%
New York State Common Retirement Fund
27
New York State Common Retirement Fund
New York
$8K – – –
Manulife (Manufacturers Life Insurance)
28
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$8K +$9.39K +49 +4,900%
MAM
29
Meeder Asset Management
Ohio
$8K +$10.2K +53 New
AIG
30
American International Group
New York
$6K – – –
NFA
31
Nationwide Fund Advisors
Ohio
$6K – – –
BA
32
BlackRock Advisors
Delaware
$4K – – –
Deutsche Bank
33
Deutsche Bank
Germany
$4K +$1.53K +8 +36%
Barclays
34
Barclays
United Kingdom
$4K +$3.64K +19 +317%
Bank of America
35
Bank of America
North Carolina
$2K +$192 +1 +7%
UBS Group
36
UBS Group
Switzerland
$1K +$1.15K +6 +200%
BNP Paribas Financial Markets
37
BNP Paribas Financial Markets
France
$370 -$383 -2 -50%
SM
38
Sabby Management
Florida
– -$492K -1,985 Closed
SIM
39
Spark Investment Management
New York
– -$54K -219 Closed
SG Americas Securities
40
SG Americas Securities
New York
– -$36K -145 Closed
TRCT
41
Tower Research Capital (TRC)
New York
– -$24K -98 Closed
ProShare Advisors
42
ProShare Advisors
Maryland
– -$23K -94 Closed
TSS
43
Two Sigma Securities
New York
– -$18K -74 Closed
RWA
44
Ropes Wealth Advisors
Massachusetts
– -$9K -37 Closed
IA
45
IFP Advisors
Florida
– -$2.87K -15 -88%
BlackRock
46
BlackRock
New York
– -$192 -1 -25%
LTFS
47
Ladenburg Thalmann Financial Services
Florida
– +$383 +2 New
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
– +$383 +2 New
1
2

ELDN Hedge Fund Activity: Q4 2016 in Review

42 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2016, worth a combined $2.43M — down 42% from $4.21M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ELDN and 6 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 19 added.

The largest buyer was Vanguard Group, adding an estimated $264K. The largest seller was Sabby Management, exiting entirely with an estimated $492K sold.

  • 42 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2016, down from 44 in Q3 2016.
  • Funds reported $2.43M of Eledon Pharmaceuticals stock for Q4 2016, down 42% quarter-over-quarter.
  • 6 funds opened new Eledon Pharmaceuticals positions in Q4 2016 and 7 closed out, a net change of -1 holder.
  • The largest Eledon Pharmaceuticals buyer in Q4 2016 was Vanguard Group, an estimated $264K added.
  • The largest Eledon Pharmaceuticals seller in Q4 2016 was Sabby Management, an estimated $492K sold.

Based on aggregated 13F filings for Q4 2016.